United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - fish oil (unii: xgf7l72m0f) (fish oil - unii:xgf7l72m0f) - omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (pnac). limitations of use: - omegaven is not indicated for the prevention of pnac. it has not been demonstrated that omegaven prevents pnac in parenteral nutrition (pn)-dependent patients [see clinical studies (14)]. - it has not been demonstrated that the clinical outcomes observed in patients treated with omegaven are a result of the omega-6:omega-3 fatty acid ratio of the product [see clinical studies (14)]. use of omegaven is contraindicated in patients with: - known hypersensitivity to fish or egg protein or to any of the active ingredients or excipients [see warnings and precautions (5.2)]. - severe hemorrhagic disorders due to a potential effect on platelet aggregation. - severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentrations greater than 1,000 mg/dl) [see warnings and precautions (5.6)]. risk summary there are no av

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - acetylcysteine -

European Union - English - EMA (European Medicines Agency)

virbac s.a. - recombinant omega interferon of feline origin - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age.catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. in cats infected by fiv, mortality was low (5%) and was not influenced by the treatment.

New Zealand - English - Ministry for Primary Industries

virbac new zealand limited - recombinant feline omega interferon - recombinant feline omega interferon 10,000 thou iu/ml - immune stimulant

United States - English - NLM (National Library of Medicine)

tmig, inc. - vitamin d (unii: 9vu1ki44gp) (vitamin d - unii:9vu1ki44gp) - vitamin d 1000 [iu] - omega-3-acid ethyl esters capsules, usp are indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia (htg). usage considerations : patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, usp and should continue this diet during treatment with omega-3-acid ethyl esters capsules, usp. laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consider

United States - English - NLM (National Library of Medicine)

key therapeutics, llc - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 1 g

United States - English - NLM (National Library of Medicine)

cardinal health - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 1 g

United States - English - NLM (National Library of Medicine)

vertical pharmaceuticals, llc - omega-3 fatty acids (unii: 71m78end5s) (omega-3 fatty acids - unii:71m78end5s), calcium ascorbate (unii: 183e4w213w) (ascorbic acid - unii:pq6ck8pd0r), calcium threonate (unii: hbb4ypo93u) (calcium cation - unii:2m83c4r6zb), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol, d- (unii: n9pr3490h9) (.alpha.-tocopherol, d- - unii:n9pr3490h9), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii - omega-3 fatty acids 200 mg - ob complete™ with dha should not be used by patients with a known hypersensitivity to any of the listed ingredients including soy and fish oil.

United States - English - NLM (National Library of Medicine)

centurion labs, llc - omega-3 fatty acids (unii: 71m78end5s) (omega-3 fatty acids - unii:71m78end5s), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), .alpha.-tocopherol, d- (unii: n9pr3490h9) (.alpha.-tocopherol, d- - unii:n9pr3490h9), cupric sulfate (unii: lrx7aj16dt) (cupric cation - unii:8cbv67279l), zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37), ferrous fumarate (unii: r5l488ry0q) (ferrous cation - unii:gw89581owr), magnesium (unii: i38zp9992a) (magnesium - unii:i38zp9992a) - omega-3 fatty acids 200 mg - indications and usage: c-nate dha is a prescription multivitamin/multimineral indicated for use in improving the nutritional status of women prior to conception, throughout pregnancy and in the postnatal period for both lactating and nonlactating mothers. contraindications: c-nate dha should not be used by patients with known history of hypersensitivity to any of the listed ingredients. pediatric use: safety and effectiveness in pediactric patients has not been established. geriactric use: no clinical studies have been performed in patients over 65 to determine whether older persons respond differently from younger persons. physicians should consider that elderly person may have decreased hepatic, renal, or cardiac function.

United States - English - NLM (National Library of Medicine)

gensavis pharmaceuticals, llc - omega-3 fatty acids (unii: 71m78end5s) (omega-3 fatty acids - unii:71m78end5s), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol (unii: h4n855pnz1) (.alpha.-tocopherol - unii:h4n855pnz1) - omega-3 fatty acids 1050 mg in 5 ml - shake well before use. as a dietary supplement for infants and children ranging from 5 to 35 pounds in weight. take as directed unless otherwise instructed by your child's physician.